A major public-private research initiative in the UK, Our Future Health, has added a new partner from industry, Swiss pharma giant Novartis (NOVN: VX).
Launched in 2022, the research project has secured the participation of millions of British people, who are submitting health data including from a finger-prick blood test.
The goal is to enable large-scale research into major health conditions, with the country’s National Health Service (NHS) set to benefit from an improved understanding of the impact of treatments on public health.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze